
Revelation Pharma Responds to HHS Enforcement Discretion for Six Peptides
National compounding pharmacy network ready to serve patients and providers under new interim policy
- HHS interim policy opens a path for 503A pharmacies to compound BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon
- Revelation Pharma’s 503A network prepared to meet new API sourcing and quality requirements from day one
- Patients gain access to six compounded peptides through licensed pharmacies under provider care
KENNESAW, Georgia (Oct. 29, 2026) – Revelation Pharma, a national network of 503A compounding pharmacies and 503B outsourcing facilities, announces it is positioned to serve patients and providers following the Department of Health and Human Services’ publication of its Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket No. HHS-OASH-2026-0496). The interim policy, signed by HHS Secretary Robert F. Kennedy Jr., identifies six peptide bulk drug substances, including BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, that state-licensed 503A pharmacies may compound without enforcement action from HHS. Revelation Pharma has been preparing for this moment and moves forward with the quality infrastructure and clinical education resources needed to deliver these therapies responsibly.
The interim policy creates a structured pathway for patients who have previously obtained peptides through unregulated, research-use-only channels to access them instead through licensed pharmacies operating under provider care. For the compounding pharmacy industry, it signals that years of scientific advocacy and regulatory engagement are beginning to yield results. Revelation Pharma contributed data to the FDA’s Pharmacy Compounding Advisory Committee process, worked to advance the case for patient access, and built the operational infrastructure to act when the opportunity arrived.
What This Moment Means for Patients
“This is a genuinely exciting moment for our patients, our providers, and our team,” said Shawn Hodges, CEO, Revelation Pharma. “We have spent the past year doing the hard work behind the scenes so that when the door opened, we could walk through it and deliver for the people who have been waiting.”
A Commitment to Quality That Protects Long-Term Access
The HHS policy includes new requirements for Active Pharmaceutical Ingredient (API) suppliers, and Revelation Pharma treats those requirements as a floor, not a ceiling. CGMP-grade peptide API sources are expected to sell material at the start of 2027, and the company’s quality team is actively reviewing qualified suppliers against FDA standards. Revelation Pharma will not rush to market at the expense of quality. The company also contributed inputs to the Peptide Council, an independent 501(c)(3) non-profit accreditation organization formed in July 2026 to establish standards for compounding pharmacies, API suppliers, and telemedicine companies operating in the peptide therapy market. To support providers and patients, Revelation Pharma offers one-on-one consultations with a team of clinical pharmacists and on-demand education through PharmAcademy, its digital learning platform.
Why Quality Standards Matter Now
“Our goal is not just to be first,” said Jon Pritchett, Chief Operating Officer, Revelation Pharma. “Our goal is to do this right so that these six peptides earn a permanent place in the category on the 503A bulks list and patients can count on access for the long haul. Every decision we make right now is about building the trust that this category needs to survive and grow.”
A Network Built for Responsible, Personalized Care
Revelation Pharma operates a nationwide network of compounding pharmacies built on personalized medicine and patient safety. The company invests in provider education, contributes data to regulatory processes, and builds the operational readiness required to meet patient demand responsibly. With the HHS Enforcement Discretion Policy now in effect, Revelation Pharma is ready to serve.